Supernus Pharmaceuticals, Inc.
SUPN
Classificação em ações
#5607
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Preço da ação
$41.34
Valor de mercado
$2.41B
Variação (1 dia)
3.75%
Variação (1 ano)
-19.39%
País
US
Negociar Supernus Pharmaceuticals, Inc. (SUPN)
Categoria
Healthcare
Número de ações em circulação para Supernus Pharmaceuticals, Inc. (SUPN)
Número de ações em circulação em October 2026: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Supernus Pharmaceuticals, Inc., o número atual de ações em circulação é 0. No final de October 2026, a empresa tinha 0 ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Supernus Pharmaceuticals, Inc. (SUPN) de 2026 a 2026
Ações em circulação no final de cada ano
| Ano | Ações em circulação | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Ações em circulação de empresas semelhantes ou concorrentes
| Empresa | Ações em circulação | Diferença | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
